Your browser doesn't support javascript.
loading
Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models.
Peinado, Paola; Andrades, Alvaro; Cuadros, Marta; Rodriguez, Maria Isabel; Coira, Isabel F; Garcia, Daniel J; Álvarez-Perez, Juan Carlos; Baliñas-Gavira, Carlos; Arenas, Alberto M; Patiño-Mercau, Juan Rodrigo; Sanjuan-Hidalgo, Juan; Romero, Octavio A; Montuenga, Luis M; Carretero, Julian; Sanchez-Cespedes, Montserrat; Medina, Pedro P.
Afiliación
  • Peinado P; Department of Biochemistry and Molecular Biology I, University of Granada, 18071 Granada, Spain.
  • Andrades A; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.
  • Cuadros M; Department of Biochemistry and Molecular Biology I, University of Granada, 18071 Granada, Spain.
  • Rodriguez MI; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.
  • Coira IF; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.
  • Garcia DJ; Health Research Institute of Granada (ibs.Granada), 18014 Granada, Spain.
  • Álvarez-Perez JC; Department of Biochemistry and Molecular Biology III and Immunology, University of Granada, 18016 Granada, Spain.
  • Baliñas-Gavira C; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.
  • Arenas AM; Health Research Institute of Granada (ibs.Granada), 18014 Granada, Spain.
  • Patiño-Mercau JR; Department of Biochemistry and Molecular Biology III and Immunology, University of Granada, 18016 Granada, Spain.
  • Sanjuan-Hidalgo J; School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland.
  • Romero OA; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland.
  • Montuenga LM; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.
  • Carretero J; Department of Biochemistry and Molecular Biology III and Immunology, University of Granada, 18016 Granada, Spain.
  • Sanchez-Cespedes M; Department of Biochemistry and Molecular Biology I, University of Granada, 18071 Granada, Spain.
  • Medina PP; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.
Cancers (Basel) ; 12(12)2020 Dec 10.
Article en En | MEDLINE | ID: mdl-33321963
Mammalian SWI/SNF (SWitch/Sucrose Non-Fermentable) complexes are ATP-dependent chromatin remodelers whose subunits have emerged among the most frequently mutated genes in cancer. Studying SWI/SNF function in cancer cell line models has unveiled vulnerabilities in SWI/SNF-mutant tumors that can lead to the discovery of new therapeutic drugs. However, choosing an appropriate cancer cell line model for SWI/SNF functional studies can be challenging because SWI/SNF subunits are frequently altered in cancer by various mechanisms, including genetic alterations and post-transcriptional mechanisms. In this work, we combined genomic, transcriptomic, and proteomic approaches to study the mutational status and the expression levels of the SWI/SNF subunits in a panel of 38 lung adenocarcinoma (LUAD) cell lines. We found that the SWI/SNF complex was mutated in more than 76% of our LUAD cell lines and there was a high variability in the expression of the different SWI/SNF subunits. These results underline the importance of the SWI/SNF complex as a tumor suppressor in LUAD and the difficulties in defining altered and unaltered cell models for the SWI/SNF complex. These findings will assist researchers in choosing the most suitable cellular models for their studies of SWI/SNF to bring all of its potential to the development of novel therapeutic applications.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: España